Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthetics Stance In NDI Guidance Raises Red Flag For Industry

This article was originally published in The Tan Sheet

Executive Summary

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.

You may also be interested in...



Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry

More than four years after beginning to revise its widely criticized initial draft guidance on NDI notifications, FDA on Aug. 11 released a second draft. "I think it is reflective of a new effort by the agency to have a dialogue with the industry," says Steve Mister, president and CEO of the Council for Responsible Nutrition.

DMAA Is Synthetic And Needs NDI Notification – Study

Botanical experts refute that DMAA is a geranium plant derivative and that the ingredient has been common in the food supply, as some supplement manufacturers have argued. “Elementary mathematics establishes that [DMAA] in dietary supplements must be synthetic,” study authors say.

DMAA Is Synthetic And Needs NDI Notification – Study

Botanical experts refute that DMAA is a geranium plant derivative and that the ingredient has been common in the food supply, as some supplement manufacturers have argued. “Elementary mathematics establishes that [DMAA] in dietary supplements must be synthetic,” study authors say.

Related Content

Topics

UsernamePublicRestriction

Register

PS105172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel